James Alyssa E, Abdalgani Manar, Khoury Paneez, Freeman Alexandra F, Milner Joshua D
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Columbia University Vagelos College of Physicians and Surgeons, Columbia University, New York, NY.
J Allergy Clin Immunol. 2024 Aug;154(2):245-254. doi: 10.1016/j.jaci.2024.05.007. Epub 2024 May 17.
Monogenic lesions in pathways critical for effector functions responsible for immune surveillance, protection against autoinflammation, and appropriate responses to allergens and microorganisms underlie the pathophysiology of inborn errors of immunity (IEI). Variants in cytokine production, cytokine signaling, epithelial barrier function, antigen presentation, receptor signaling, and cellular processes and metabolism can drive autoimmunity, immunodeficiency, and/or allergic inflammation. Identification of these variants has improved our understanding of the role that many of these proteins play in skewing toward T2-related allergic inflammation. Early-onset or atypical atopic disease, often in conjunction with immunodeficiency and/or autoimmunity, should raise suspicion for an IEI. This becomes a diagnostic dilemma if the initial clinical presentation is solely allergic inflammation, especially when the prevalence of allergic diseases is becoming more common. Genetic sequencing is necessary for IEI diagnosis and is helpful for early recognition and implementation of targeted treatment, if available. Although genetic evaluation is not feasible for all patients with atopy, identifying atopic patients with molecular immune abnormalities may be helpful for diagnostic, therapeutic, and prognostic purposes. In this review, we focus on IEI associated with T2-driven allergic manifestations and classify them on the basis of the affected molecular pathways and predominant clinical manifestations.
免疫监视、抵御自身炎症以及对过敏原和微生物作出适当反应所必需的效应器功能相关途径中的单基因病变,是先天性免疫缺陷(IEI)病理生理学的基础。细胞因子产生、细胞因子信号传导、上皮屏障功能、抗原呈递、受体信号传导以及细胞过程和代谢方面的变异,可引发自身免疫、免疫缺陷和/或过敏性炎症。对这些变异的识别,增进了我们对许多此类蛋白质在偏向T2相关过敏性炎症过程中所起作用的理解。早发性或非典型特应性疾病,常伴有免疫缺陷和/或自身免疫,应引起对IEI的怀疑。如果初始临床表现仅为过敏性炎症,尤其是在过敏性疾病患病率日益普遍的情况下,这就会成为一个诊断难题。基因测序对于IEI诊断是必要的,并且如果有可用的靶向治疗方法,有助于早期识别和实施靶向治疗。虽然并非所有特应性患者都可行基因评估,但识别出有分子免疫异常的特应性患者可能有助于诊断、治疗和预后判断。在本综述中,我们聚焦于与T2驱动的过敏表现相关的IEI,并根据受影响的分子途径和主要临床表现对其进行分类。